5 Stocks, A 10% Average Yield, And 60 Dividend Checks a Year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 19 2025
0mins
Should l Buy DOC?
Source: NASDAQ.COM
Monthly Dividend Stocks: The article discusses five monthly dividend-paying stocks with yields ranging from 5.8% to 16.3%, highlighting the advantages of consistent monthly income over traditional quarterly dividends.
Stock Analysis: It provides insights into specific companies like Healthpeak Properties, EPR Properties, Gladstone Commercial, Prospect Capital, and AGNC Investment Corp., detailing their business models, dividend yields, and potential risks or growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOC
Wall Street analysts forecast DOC stock price to rise
12 Analyst Rating
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 16.280
Low
16.71
Averages
19.23
High
21.00
Current: 16.280
Low
16.71
Averages
19.23
High
21.00
About DOC
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. It owns, operates, and develops real estate focused on healthcare discovery and delivery. The Company’s segments include Lab, Outpatient medical and continuing care retirement community (CCRC). The Outpatient medical segment owns, operates, and develops outpatient medical buildings, hospitals, and lab buildings. The lab segment properties contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. Its CCRC segment is a retirement community that include independent living, assisted living, memory care, and skilled nursing units to provide a continuum of care in an integrated campus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SPHD ETF 52-Week Price Analysis
- Price Range Analysis: The SPHD ETF has a 52-week low of $43.39 and a high of $52.38, with the latest trade at $52.36, indicating stability near its high point, which may attract investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market dynamics.
See More
Two REITs Appearing Promising in a Steady Interest Rate Climate
Trump Administration's Impact on REITs: The nomination of Kevin Warsh as the next chair of the Federal Reserve may provide clarity and predictability regarding interest rate cuts, which is crucial for Real Estate Investment Trusts (REITs) that benefit from lower interest rates.
Performance of Simon Property Group: Simon Property Group (SPG) has shown promising results, catering to high-end consumers and reporting solid earnings, indicating a strong demand for retail spaces despite economic pressures.
Healthpeak Properties' Growth: Healthpeak Properties (DOC), specializing in healthcare-related real estate, is experiencing growth driven by the aging population and increasing demand for healthcare facilities, suggesting a stable cash flow.
Investment Strategies: Analysts recommend a balanced investment approach between SPG and DOC, highlighting the potential for growth in both retail and healthcare sectors, while also noting the importance of understanding consumer spending patterns.
See More
Healthpeak Properties Q4 2025 Earnings Call Insights
- Merger Synergies: Healthpeak realized over $70 million in synergies from its merger with Physicians Realty Trust, driving strong performance in the outpatient medical segment, which achieved a 3.9% same-store cash NOI growth in Q4 2025, showcasing the company's competitiveness in the healthcare asset market.
- Outpatient Medical Growth: In 2025, the outpatient medical segment delivered 4.9 million square feet of leasing, including 1 million square feet of new leases, with a tenant retention rate of 79%, indicating the company's benefit from ongoing policy support and market demand for lower-cost, convenient outpatient settings.
- Lab Segment Challenges: Despite facing operational headwinds in the lab segment during the first half of 2025, management noted that new deliveries are expected to trend towards zero in the coming years, which should help alleviate supply overhang and drive long-term value growth.
- Future Outlook: Healthpeak forecasts adjusted FFO per share for 2026 to range between $1.70 and $1.74, and while facing ongoing pressures in the lab segment, management remains optimistic about growth in outpatient and senior housing sectors, emphasizing the importance of capital recycling and operational leadership.
See More
Healthpeak Properties Upgraded to Overweight Rating
- Rating Upgrade: Healthpeak Properties (DOC) has received an overweight rating, reflecting analysts' optimistic outlook on its future performance, which is likely to attract more investor attention.
- Price Target Analysis: The company's average price target is set at $19.73, indicating a positive sentiment regarding its potential price appreciation, which could drive short-term stock price increases.
- Market Reaction: The rating upgrade may enhance market confidence in Healthpeak, potentially increasing its stock liquidity and trading volume, thereby solidifying its position in the Real Estate Investment Trust (REIT) sector.
- Investor Strategy: With the rating elevation, investors may reassess their portfolios and increase their holdings in Healthpeak, aiming for higher returns in the future.
See More
Healthpeak Properties Q4 Earnings Beat Expectations but Guidance Falls Short
- Financial Performance Beat: Healthpeak Properties reported a Q4 adjusted FFO of $0.47 per share, slightly exceeding Wall Street's expectation of $0.46, indicating operational improvements despite ongoing challenges in the market.
- Revenue Growth: The company achieved Q4 revenue of $719.4 million, up from $687.3 million in Q3, reflecting stability and diversification in revenue streams, although it fell short of the $698 million reported in the same quarter last year.
- Cautious Future Outlook: For FY26, Healthpeak projects adjusted FFO per share between $1.70 and $1.74, below the average analyst estimate of $1.83, suggesting a cautious stance on future market conditions that may impact investor confidence.
- Leasing Activity: New and renewal lease executions totaled 2.1 million square feet in Q4, significantly up from 1.5 million in Q3, although the lab segment experienced a 1.7% decline in cash releasing spreads on renewals, indicating increased competitive pressure in the leasing market.
See More
Healthpeak Properties Q4 Earnings Exceed Expectations
- Strong Financial Performance: Healthpeak Properties reported a Q4 FFO of $0.47, beating expectations by $0.01, indicating the company's robust performance in the market.
- Revenue Growth: The company achieved Q4 revenue of $719.4 million, reflecting a 3.1% year-over-year increase and surpassing market expectations by $32.12 million, showcasing its ongoing growth potential.
- 2026 Guidance: Healthpeak projects diluted earnings per share for 2026 to be between $0.34 and $0.38, with diluted Nareit FFO per share expected at $1.70 to $1.74, although below the $1.83 consensus, reflecting cautious market sentiment regarding future growth.
- Cash Flow Outlook: The total merger-combined same-store cash NOI growth is projected to be between -1% and 1%, indicating the company's adaptability amid market fluctuations while also hinting at potential challenges ahead.
See More
SPHD ETF 52-Week Price Analysis
- Price Range Analysis: The SPHD ETF has a 52-week low of $43.39 and a high of $52.38, with the latest trade at $52.36, indicating stability near its high point, which may attract investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market dynamics.
See More
Two REITs Appearing Promising in a Steady Interest Rate Climate
Trump Administration's Impact on REITs: The nomination of Kevin Warsh as the next chair of the Federal Reserve may provide clarity and predictability regarding interest rate cuts, which is crucial for Real Estate Investment Trusts (REITs) that benefit from lower interest rates.
Performance of Simon Property Group: Simon Property Group (SPG) has shown promising results, catering to high-end consumers and reporting solid earnings, indicating a strong demand for retail spaces despite economic pressures.
Healthpeak Properties' Growth: Healthpeak Properties (DOC), specializing in healthcare-related real estate, is experiencing growth driven by the aging population and increasing demand for healthcare facilities, suggesting a stable cash flow.
Investment Strategies: Analysts recommend a balanced investment approach between SPG and DOC, highlighting the potential for growth in both retail and healthcare sectors, while also noting the importance of understanding consumer spending patterns.
See More
Healthpeak Properties Q4 2025 Earnings Call Insights
- Merger Synergies: Healthpeak realized over $70 million in synergies from its merger with Physicians Realty Trust, driving strong performance in the outpatient medical segment, which achieved a 3.9% same-store cash NOI growth in Q4 2025, showcasing the company's competitiveness in the healthcare asset market.
- Outpatient Medical Growth: In 2025, the outpatient medical segment delivered 4.9 million square feet of leasing, including 1 million square feet of new leases, with a tenant retention rate of 79%, indicating the company's benefit from ongoing policy support and market demand for lower-cost, convenient outpatient settings.
- Lab Segment Challenges: Despite facing operational headwinds in the lab segment during the first half of 2025, management noted that new deliveries are expected to trend towards zero in the coming years, which should help alleviate supply overhang and drive long-term value growth.
- Future Outlook: Healthpeak forecasts adjusted FFO per share for 2026 to range between $1.70 and $1.74, and while facing ongoing pressures in the lab segment, management remains optimistic about growth in outpatient and senior housing sectors, emphasizing the importance of capital recycling and operational leadership.
See More
Healthpeak Properties Upgraded to Overweight Rating
- Rating Upgrade: Healthpeak Properties (DOC) has received an overweight rating, reflecting analysts' optimistic outlook on its future performance, which is likely to attract more investor attention.
- Price Target Analysis: The company's average price target is set at $19.73, indicating a positive sentiment regarding its potential price appreciation, which could drive short-term stock price increases.
- Market Reaction: The rating upgrade may enhance market confidence in Healthpeak, potentially increasing its stock liquidity and trading volume, thereby solidifying its position in the Real Estate Investment Trust (REIT) sector.
- Investor Strategy: With the rating elevation, investors may reassess their portfolios and increase their holdings in Healthpeak, aiming for higher returns in the future.
See More
Healthpeak Properties Q4 Earnings Beat Expectations but Guidance Falls Short
- Financial Performance Beat: Healthpeak Properties reported a Q4 adjusted FFO of $0.47 per share, slightly exceeding Wall Street's expectation of $0.46, indicating operational improvements despite ongoing challenges in the market.
- Revenue Growth: The company achieved Q4 revenue of $719.4 million, up from $687.3 million in Q3, reflecting stability and diversification in revenue streams, although it fell short of the $698 million reported in the same quarter last year.
- Cautious Future Outlook: For FY26, Healthpeak projects adjusted FFO per share between $1.70 and $1.74, below the average analyst estimate of $1.83, suggesting a cautious stance on future market conditions that may impact investor confidence.
- Leasing Activity: New and renewal lease executions totaled 2.1 million square feet in Q4, significantly up from 1.5 million in Q3, although the lab segment experienced a 1.7% decline in cash releasing spreads on renewals, indicating increased competitive pressure in the leasing market.
See More
Healthpeak Properties Q4 Earnings Exceed Expectations
- Strong Financial Performance: Healthpeak Properties reported a Q4 FFO of $0.47, beating expectations by $0.01, indicating the company's robust performance in the market.
- Revenue Growth: The company achieved Q4 revenue of $719.4 million, reflecting a 3.1% year-over-year increase and surpassing market expectations by $32.12 million, showcasing its ongoing growth potential.
- 2026 Guidance: Healthpeak projects diluted earnings per share for 2026 to be between $0.34 and $0.38, with diluted Nareit FFO per share expected at $1.70 to $1.74, although below the $1.83 consensus, reflecting cautious market sentiment regarding future growth.
- Cash Flow Outlook: The total merger-combined same-store cash NOI growth is projected to be between -1% and 1%, indicating the company's adaptability amid market fluctuations while also hinting at potential challenges ahead.
See More
